We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares
CANF

13 hedge funds and large institutions have $1.09M invested in Can-Fite BioPharma American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

152% more capital invested

Capital invested by funds: $434K → $1.09M (+$660K)

117% more funds holding

Funds holding: 6 → 13 (+7)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
13
Holders Change
+7
Holders Change %
+116.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAN
Cetera Advisor Networks
California
+$347K
2
Morgan Stanley
Morgan Stanley
New York
+$135K
3
Citadel Advisors
Citadel Advisors
Florida
+$130K
4
TSS
Two Sigma Securities
New York
+$117K
5
Stifel Financial
Stifel Financial
Missouri
+$26K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$212K
2
VF
Virtu Financial
New York
-$60.3K
3
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$31K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAN
1
Cetera Advisor Networks
California
$395K +$347K +800 New
Morgan Stanley
2
Morgan Stanley
New York
$197K +$135K +311 +353%
Citadel Advisors
3
Citadel Advisors
Florida
$148K +$130K +300 New
TSS
4
Two Sigma Securities
New York
$134K +$117K +270 New
VF
5
Virtu Financial
New York
$114K -$60.3K -139 -38%
Stifel Financial
6
Stifel Financial
Missouri
$30K +$26K +60 New
XT
7
XTX Topco
Cayman Islands
$28K +$24.3K +56 New
Jane Street
8
Jane Street
New York
$26K +$23K +53 New
Citigroup
9
Citigroup
New York
$14K +$12.2K +28 New
Wells Fargo
10
Wells Fargo
California
$4K +$3.47K +8 New
APA
11
American Portfolios Advisors
New York
$2.72K +$2.6K +6 New
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.32K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
– -$212K -594 Closed
SFI
14
Susquehanna Fundamental Investments
Pennsylvania
– -$31K -87 Closed
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$27K -77 Closed
WAP
16
Wealthcare Advisory Partners
Pennsylvania
– +$434 +1 New

CANF Hedge Fund Activity: Q1 2021 in Review

13 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2021, worth a combined $1.09M — up 152% from $434K a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CANF positions and 3 closed out — a net gain of 7 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Cetera Advisor Networks, opening a new position worth an estimated $347K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $212K sold.

  • 13 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2021, up from 6 in Q4 2020.
  • Funds reported $1.09M of Can-Fite BioPharma American Depositary Shares stock for Q1 2021, up 152% quarter-over-quarter.
  • 10 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2021 and 3 closed out, a net change of +7 holders.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2021 was Cetera Advisor Networks, an estimated $347K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2021 was Renaissance Technologies, an estimated $212K sold.

Based on aggregated 13F filings for Q1 2021.